
GKB Ophthalmics Ltd Downgraded to Sell Amid Mixed Financial Signals and Weak Fundamentals
2026-06-09 08:36:20GKB Ophthalmics Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 8 June 2026, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent positive earnings growth and attractive valuation multiples, the company’s weak long-term fundamentals and persistent underperformance against benchmarks have prompted a cautious stance.
Read full news article
GKB Ophthalmics Ltd Upgraded to Hold on Improved Valuation and Financial Trends
2026-06-01 08:11:28GKB Ophthalmics Ltd has seen its investment rating upgraded from Sell to Hold as of 29 May 2026, reflecting a marked improvement in valuation metrics and financial performance despite ongoing challenges in long-term fundamentals and market returns. The company’s mojo score has risen to 58.0, signalling a more balanced outlook for investors amid a micro-cap classification and a recent share price decline of 1.95%.
Read full news article
GKB Ophthalmics Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-06-01 08:01:56GKB Ophthalmics Ltd has witnessed a significant improvement in its valuation parameters, transitioning from a risky to a very attractive investment proposition. With a current price of ₹63.73 and a micro-cap market classification, the healthcare services company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to historical levels and peer averages, prompting an upgrade in its Mojo Grade from Sell to Hold as of 29 May 2026.
Read full news articleAre GKB Ophthalmics Ltd latest results good or bad?
2026-05-29 19:41:33GKB Ophthalmics Ltd's latest financial results for the quarter ended March 2026 reveal significant operational challenges. The company reported consolidated net sales of ₹29.79 crores, reflecting a notable decline of 47.54% quarter-on-quarter and a year-on-year decrease of 3.97%. This marks the lowest quarterly revenue in the past seven quarters, indicating potential issues with order execution and customer retention. Despite the revenue downturn, GKB Ophthalmics achieved a consolidated net profit of ₹0.19 crores, a recovery from losses in previous quarters. However, this profit represents a sharp decline of 56.82% from the previous quarter and a staggering drop of 105.35% year-on-year, highlighting the volatility in profitability. The operating margin, excluding other income, improved to 10.44%, the highest in seven quarters, suggesting some progress in cost management and operational efficiency. However...
Read full news article
GKB Ophthalmics Q4 FY26: Profit Recovery Masks Deeper Concerns About Sustainability
2026-05-29 09:36:45GKB Ophthalmics Ltd., a Goa-based healthcare services company with a market capitalisation of ₹32.00 crores, reported a consolidated net profit of ₹0.19 crores in Q4 FY26 (Mar'26), marking a dramatic reversal from the ₹3.55 crore loss recorded in the same quarter last year. However, the sequential performance tells a concerning story, with profits plunging 56.82% quarter-on-quarter from ₹0.44 crores in Q3 FY26 (Dec'25), raising questions about the sustainability of this recovery.
Read full news article
GKB Ophthalmics Ltd Upgraded to Sell on Technical Improvements Despite Fundamental Challenges
2026-05-22 08:13:14GKB Ophthalmics Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 May 2026, driven primarily by a shift in technical indicators. While the company’s financial fundamentals remain weak, recent positive technical trends have prompted a reassessment of its near-term outlook. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.
Read full news article
GKB Ophthalmics Ltd is Rated Strong Sell
2026-05-13 10:11:11GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 Dec 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
GKB Ophthalmics Ltd is Rated Strong Sell
2026-04-30 10:11:00GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 December 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article
GKB Ophthalmics Ltd is Rated Strong Sell
2026-04-10 10:10:57GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 Dec 2024, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news articleAnnouncement under Regulation 30 (LODR)-Newspaper Publication
01-Jun-2026 | Source : BSEPlease find enclosed copies of newspaper cuttings of the extract of statement of audited Standalone and Consolidated Financial Results for the year ended March 31 2026 published in Free Press Journal (Mumbai Edition) and on Pudhari (Marathi) dated May 29 2026. Please acknowledge receipt.
Compliances-Reg.24(A)-Annual Secretarial Compliance
23-May-2026 | Source : BSEPursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 enclosed please find the Annual Secretarial Compliance Report for the year ended March 31 2026 issued by Ms. Girija Nagvekar Practicing Company Secretary and Secretarial Auditor of the Company. Kindly take the above information on record.
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31 2026.
04-May-2026 | Source : BSEGKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results of the company for the qurter and year ended March 31 2026. The Notice can be accessed at the Companys website at www.gkb.net Further notice is hereby given with reference to the above meeting of the Board of Directors that the Trading Window for dealing with equity shares of the Company by designated persons under the SEBI (Prohibition of Insider Trading) Regulation 2015 had been closed from April 01 2026 will now re-open after the completion of 48 hours from the date of submission of financial results to the Stock Exchange. This communication has been sent to all the Directors sand all the designated emplyoyees of the Company.
Corporate Actions
No Upcoming Board Meetings
GKB Ophthalmics Ltd has declared 12% dividend, ex-date: 21 Sep 10
No Splits history available
No Bonus history available
No Rights history available






